Literature DB >> 19505744

Drugs, sex, money and power: an HPV vaccine case study.

Marion Haas1, Toni Ashton, Kerstin Blum, Terkel Christiansen, Elena Conis, Luca Crivelli, Meng Kin Lim, Melanie Lisac, Margaret Macadam, Sophia Schlette.   

Abstract

In this paper we compare the experiences of seven industrialized countries in considering approval and introduction of the world's first cervical cancer-preventing vaccine. Based on case studies, articles from public agencies, professional journals and newspapers we analyse the public debate about the vaccine, examine positions of stakeholder groups and their influence on the course and outcome of this policy process. The analysis shows that the countries considered here approved the vaccine and established related immunization programs exceptionally quickly even though there still exist many uncertainties as to the vaccine's long-term effectiveness, cost-effectiveness and safety. Some countries even bypassed established decision-making processes. The voice of special interest groups has been prominent in all countries, drawing on societal values and fears of the public. Even though positions differed among countries, all seven decided to publicly fund the vaccine, illustrating a widespread convergence of interests. It is important that decision-makers adhere to transparent and robust guidelines in making funding decisions in the future to avoid capture by vested interests and potentially negative effects on access and equity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19505744     DOI: 10.1016/j.healthpol.2009.05.002

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  13 in total

1.  Provincial elections and timing of cancer drug funding.

Authors:  A Srikanthan; S S Gill; K K W Chan
Journal:  Curr Oncol       Date:  2016-06-09       Impact factor: 3.677

2.  Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh.

Authors:  Abdur Razzaque Sarker; Marufa Sultana; Rashidul Alam Mahumud; Robert Van Der Meer; Alec Morton
Journal:  Hum Vaccin Immunother       Date:  2017-12-12       Impact factor: 3.452

3.  Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study.

Authors:  Leah M Smith; Jay S Kaufman; Erin C Strumpf; Linda E Lévesque
Journal:  CMAJ       Date:  2014-12-08       Impact factor: 8.262

4.  Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders.

Authors:  Don L Douglas; Denise A DeRoeck; Richard T Mahoney; Ole Wichmann
Journal:  PLoS Negl Trop Dis       Date:  2013-03-14

5.  Evidence and policymaking: The introduction of MMR vaccine in the Netherlands.

Authors:  Stuart Blume; Janneke Tump
Journal:  Soc Sci Med       Date:  2010-07-13       Impact factor: 4.634

6.  Explaining variation in the uptake of HPV vaccination in England.

Authors:  Varun M Kumar; David K Whynes
Journal:  BMC Public Health       Date:  2011-03-22       Impact factor: 3.295

7.  Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal.

Authors:  Raymond Hutubessy; Ana Maria Henao; Pem Namgyal; Vasee Moorthy; Joachim Hombach
Journal:  BMC Med       Date:  2011-05-12       Impact factor: 8.775

8.  Global challenges of implementing human papillomavirus vaccines.

Authors:  Janice E Graham; Amrita Mishra
Journal:  Int J Equity Health       Date:  2011-06-30

9.  Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.

Authors:  Mark Jit; Ruth Chapman; Owain Hughes; Yoon Hong Choi
Journal:  BMJ       Date:  2011-09-27

10.  The timing of drug funding announcements relative to elections: a case study involving dementia medications.

Authors:  Sudeep S Gill; Neeraj Gupta; Chaim M Bell; Paula A Rochon; Peter C Austin; Andreas Laupacis
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.